WO2006048146A1 - Quinoline as allosteric enhancers of the gaba-b receptors - Google Patents
Quinoline as allosteric enhancers of the gaba-b receptors Download PDFInfo
- Publication number
- WO2006048146A1 WO2006048146A1 PCT/EP2005/011403 EP2005011403W WO2006048146A1 WO 2006048146 A1 WO2006048146 A1 WO 2006048146A1 EP 2005011403 W EP2005011403 W EP 2005011403W WO 2006048146 A1 WO2006048146 A1 WO 2006048146A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- quinolin
- methyl
- ethanone
- trifluoro
- Prior art date
Links
- 0 *C(c1c(*I)nc(cc(*)c(N(*)*)c2)c2c1-c1ccc(*)c(*)c1)=O Chemical compound *C(c1c(*I)nc(cc(*)c(N(*)*)c2)c2c1-c1ccc(*)c(*)c1)=O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to compounds of formula I
- R 1 is hydrogen, C 1 -C 7 alkyl, Ci-C 7 haloalkyl, di(Ci-C 7 )alkylamino, C 3 -C 8 cycloalkyl, or 5 or 6 membered heterocycloalkyl;
- R 2 is Ci-C 7 alkyl, aryl, C 1 -C 7 alkoxy(Ci-C 7 )alkyl, C 1 -C 7 haloalkyl or C 3 -C 8 cycloalkyl;
- R 3 , R 4 are each independently hydrogen, halo, hydroxy, Ci-C 7 alkoxy, Ci-C 7 haloalkoxy, di(Ci-C 7 )alkylamino, Ci-C 7 alkylsulfonyl, or 5 or 6 membered heterocycloalkyl;
- R 5 is hydrogen, halo, Ci-C 7 alkyl, Ci-C 7 alkoxy, Ci-C 7 haloalkoxy, or aryloxy, or is -NR 7 R 8 wherein R 7 and R 8 are Ci-C 7 alkyl, or R 7 and R 8 may, together with the nitrogen atom to which they are attached, form or a 4 to 8 membered heterocycloalkyl group which may be substituted by one or more subsituent(s) selected from the group consisting of halo, Ci-C 7 alkyl, Ci-C 7 alkoxy, hydroxy, phenyl and di(Ci-C 7 )alkylamino;
- R 6 is hydrogen or together with R 5 may form a 5 or 6 membered heterocycloalkyl group which may be substituted by one or more halogen; and pharmaceutically acceptable acid addition salts thereof, excluding the following compounds: l-(6-Chloro-2-methyl-4-phenyl-quinolin-3-yl)-
- the compounds of formula I and their salts are distinguished by valuable therapeutic properties. It has been found that the compounds are active on the GABA B receptor.
- GABA ⁇ -Aminobutyric acid
- GABA the most abundant inhibitory neurotransmitter, activates both ionotropic GABA A/C and metabotropic GABA B receptors (Hill ccnd Bowery, Nature, 290, 149-152, 1981).
- GABA B receptors that are present in most regions of the mammalian brain on presynaptic terminals and postsynaptic neurons are involved in the fine-tuning of inhibitory synaptic transmission. Presynaptic GABA B receptors through modulation of high-voltage activated Ca 2+ channels (P/Q- and N- type) inhibit the release of many neurotransmitters.
- GABA B receptors activates G-protein coupled inwardly rectifying K+ (GIRK) channel and regulates adenylyl cyclase (B ⁇ llinton et al., Trends Neurosci., 24, 277-282, 2001; Bowery et al, Pharmacol. Rev.. 54, 247-264, 2002). Because the GABA B receptors are strategically located to modulate the activity" of various neurotransmitter systems, GABA B receptor ligands hence could have potential therapeutics in the treatment of anxiety, depression, epilepsy, schizophrenia and cognitive disorders (Vacher and Bettler, Curr. Drug Target, CNS Neurol. Disord. 2, 248- 259, 2003; Bettler et al, Physiol Rev. 84, 835-867, 2004).
- GABA B receptors are heteromeric structures composed of two types of subunits, GAB A 5 Rl and GABA B R2 subunits (Kaupmann et al, Nature, 386, 239-246, 1997 and Nature, 396, 683-687, 1998).
- the structure of GABA B R1 and R2 show that they belong to a family of G-protein coupled receptors (GPCRs) called family 3.
- GPCRs G-protein coupled receptors
- Other members of the family 3 GPCRs include the metabotropic glutamate (mGlul-8), Calcium-sensing, vomeronasal, pheromone and putative taste receptors (Pin et al, Pharmaco.. Ther. 98, 325-354, 2003).
- the family 3 receptors are characterized by two distinctly separated topological domains: an exceptionally long extracellular amino-terminal domain (ATD, 500-600 amino acids), which contains a venus flytrap module for the agonist binding (orthosteric site) (Galvez et al, T- Biol. Chem., 275, 41166-41174, 2000) and the 7TM helical segments plus intracellular carboxyl- terminal domain that is involved in receptor activation and G-protein coupliog.
- ATD extracellular amino-terminal domain
- 6 venus flytrap module for the agonist binding (orthosteric site)
- 7TM helical segments plus intracellular carboxyl- terminal domain that is involved in receptor activation and G-protein coupliog.
- the mechanism of receptor activation by agonist in GABA B R1R2 heterodimer is unique among the GPCRs.
- GABA ⁇ Rl subunit binds to GABA, while the GABA ⁇ R2 is responsible for coupling and activation of G-protein (Havlickova etat, MoI. Pharmacol. 62, 343-350, 2002; KniazatoralJ. Neurosci, 22, 7352-7361, 2002).
- GABA B R1 knock ⁇ out mice exhibit spontaneous seizures and hyperalgesia. These KO mice have lost all the biochemical and electrophysiological GABA B responses.
- the GABA B RI KO mice were more anxious in two anxiety paradigm, namely the light-dark box (decreased time in light) and staircase tests (decreased rears and steps climbed). They showed a clear impairment of passive avoidance performance model indicating impaired memory processes.
- the GABA B RI KO also displayed increased hyperlocomotion and hyperactivity in new environment.
- the GABA B RI gene is mapped to chromosome 6p21.3, which is within the HLA class I, a region with linkage for schizophrenia, epilepsy and dyslexia (Peters etat, Neurogenetics, 2, 47-54, 1998). Mondabon et al., Am. J. Med. Genet 122B/1, 134, 2003 have reported about a weak association of the Ala20Val polymorphism OfGABAsRl gene with schizophrenia. Moreover, Gassmann et al, J Neurosci. 24, 6086-6097, 2004 has shown that GABA B R2KO mice suffer from spontaneous seizures, hyperalgesia, hyperlocomotor activity and severe memory impairment, comparable to GABA B RIKO mice. Therefore, heteromeric GABA B R1R2 receptors are responsible for these phenotypes.
- baclofen was found to be an effective and well- tolerated treatment. It resulted in significant improvements in the overall symptoms of PTSD, most notably the avoidance, emotional numbing and hyperarousal symptoms and also in reduced accompanying anxiety and depression (Drake et al, Ann. Pharmacother. 37., 1177-1181, 2003).
- baclofen was able to reverse the reduction in prepulse inhibition (PPI) of the acoustic startle response induced by dizocilpine, but not by apomorphine in rat PPI model of psychosis (Bortolato etal, Psychopharmacolog ⁇ , 171, 322-330, 2004). Therefore, GABA B receptor agonist has a potential in the pharmacological therapy of psychotic disorders.
- PPI prepulse inhibition
- Baclofen has a number of side-effects including the poor blood-brain -barrier penetration, very short duration of action and narrow therapeutic window (muscle relaxation, sedation and tolerance) that limit its utility.
- Urwyler et al, MoI. Pharmacol, 60, 963-971, 2001 have reported on a novel class of GABA B receptor ligands, called positive allosteric modulators, CGP7930 [2,6-di-tert- butyl-4-( 3 -hydroxy-2,2-dimethyl-propyl) -phenol] and its aldehyde analogue CGP13501.
- These ligands have no effect on their own at GABA B receptors, but in concert with endogenous GABA, they increase both the potency and maximal efficacy of GABA at the GABA B R1R2 (Pin et al, MoI. Pharmacol, 60, 881-884, 2001).
- GS39783 did not have any effect on cognition performance as assessed by passive avoidance behavioral test in mice and rats. Furthermore, GS39783 exhibited anxiolytic-like effects in the elevated plus maze (rat), elevated zero maze (mice and rats), and the stress-induced hyperthermia (mice) test paradigms. Therefore, GS39783 represents a novel anxiolytic without side-effects associated with baclofen or benzodiazepines (Cr ⁇ an et al, J
- mGlul receptor Knoflach et al, Proc. Natl. Acad. ScL, USA, 98, 13402-13407, 2001; Wichmann et al, Farmaco, 57, 989-992, 2002
- NPS R- 467 and NPS R-5608 Calcium-sensing receptor
- mGlu2 receptor [LY487379, N-(4-(2-methoxyphenoxy)-phenyl- ⁇ T-(2,2,2- trifluoroethylsulfonyl)-pyrid-3-ylmethylamine and its analogs] (WO 01/56990, Potentiators of glutamate receptors) and mGlu5 receptor (CPPHA, AT- ⁇ 4-chloro-2-[(l,3- dioxo-l,3-
- Objects of the invention are the compounds of formula I and pharmaceutically acceptable acid addition salts thereof, the preparation of the compounds of formula I and salts thereof, medicaments containing a compound of formula I or a pharmaceutically acceptable acid addition salts thereof.
- a further object of the invention is the use of the compound of formula I or of a compound selected from the group consisting of: l-(6-Chloro-2-methyl-4-phenyl-quinolin-3-yl)-ethanone; l-(6-Bromo-4-phenyl-2-piperidin-l-yl-quinolin-3-yl)-ethanone; l-[4-(4-Chloro-phenyl)-2-mefhyl-quinoHn-3-yl]-ethanone; l-(6-Bromo-2-methyl-4-phenyl-quinolin-3-yl)-ethanone; l-(2,6-Dimethyl-4-phenyl-quinolin-3-yl)-ethanone; and l-(2-Methyl-4-phenyl-6-trifiuoromethoxy-quinolin-3-yl)-ethanone, and acceptable acid addition salts thereof for the manufacture of such medicaments useful in the control or prevention
- Aryl means a monovalent cyclic aromatic hydrocarbon moiety.
- Preferred aryls include, but are not limited to, optionally substituted phenyl or naphthyl, as well as those aryl groups specifically illustrated by the examples herein below.
- Examples of subsitutents for aryl groups are hydroxy, halo, C 1 -C 7 alkyl, C 1 -C 7 haloalkyl, C 1 -C 7 alkoxy, Ci-C 7 haloalkoxy, Ci-C 7 alkoxyalkyl, Ci-C 7 alkylsulfonyl, di(Q- C 7 )alkylamino or C 3 -C 8 cycloalkyl.
- aryloxy denotes an aryl group wherein the aryl group is as defined above and the aryl group is connected via an oxygen atom. Prefered aryloxy is PhO-.
- Ci-C 7 alkyl denotes a straight- or branched-carbon chain group containing from 1 to 7 carbon atoms, for example, methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl, n-hexyl as well as those specifically illustrated by the examples herein below.
- Ci-C 7 haloalkyl denotes a Ci-C 7 alkyl group as defined above which is substituted by one or more halogen.
- Examples of Ci-C 7 haloalkyl include but are not limited to methyl, ethyl, propyl, isopropyl, isobutyl, sec-butyl, tert-butyl, pentyl or n-hexyl substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
- Prefered Ci-C 7 haloalkyl are difluoro- or trifhioro-methyl or ethyl.
- Ci-C 7 alkoxy denotes a group wherein the alkyl group is as defined above and the alkyl group is connected via an oxygen atom.
- Prefered alkoxy are MeO- and Et-O as well as those groups specifically illustrated by the examples herein below.
- Ci-C 7 haloalkoxy denotes a CrC 7 alkoxy group as defined above which is substituted by one or more halogen.
- Examples of Ci-C 7 haloalkoxy include but are not limited to methoxy or ethoxy, substituted by one or more Cl, F, Br or I atom(s) as well as those groups specifically illustrated by the examples herein below.
- Prefered Ci-C 7 haloalkoxy are difluoro- or trifluoro-methoxy or ethoxy.
- ⁇ alogen denotes chlorine, iodine, fluorine and bromine.
- C 1 -C 7 alkoxyalkyl denotes a C 1 -C 7 alkyl group as defined herein above which is substituted by a Ci-C 7 alkoxy group as defined herein above.
- Ci-C 7 alkylsulfonyl denotes a sulfonyl group which is substituted by a Q-C 7 alkyl group as defined herein above.
- Examples of Ci-C 7 alkylsulfonyl include but are not limited to methylsulfphonyl and ethylsulfonyl as well as those groups specifically illustrated by the examples herein below.
- di(Ci-C 7 )alkylamino denotes a -NR 7 R 8 group, wherein R 7 and R 8 are Ci-C 7 alkyl groups as defined herein above.
- Examples of di(Ci-C 7 )alkylamino groups include but are not limited to di(methyl)amino, di(ethyl)amino, methylethylamino, as well as those groups specifically illustrated by the examples herein below.
- Haldroxy denotes a —OH group.
- C 3 -C 8 cycloalkyl denotes a saturated carbon cyclic ring having 3 to 8 carbon atoms as ring members and includes but is not limited to cyclopropyl, cyclobutyl, cydopentyl, cyclohexyl, cycloheptyl, as well as those groups specifically illustrated by the examples herein below.
- 4 to 8 membered heterocyclo alkyl denote a saturated mono- or bi-cyclic ring comprising from 1 to 7 carbon atoms as ring members, the other remaining ring member atoms being selected from one or more O, N and S.
- Preferred 4 to 8 membered heterocycloalkyl groups are 5 or 6 membered heterocycloalkyl groups.
- Examples of 4 to 8 and 5 or 6 membered heterocycloalkyl groups include but are not limited to optionally substituted azetidinyl, piperidinyl, piperazinyl, homopiperazinyl, azepinyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, pyridinyl, pyridazinyl, pyrimidinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinuclidinyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazolylidinyl, benzothiazolidinyl, benzoazolylidinyl, dihydrofuryl, tetrahydrofuryl, dihydropyranyl, tetrahydropyranyl, thiomorph
- R 6 together with R 5 form a 5 or 6 membered heterocycloalkyl group denotes 5 or 6 membered heterocycloalkyl groups as defined above which is fused to the quinoline group via R 5 and R 6 .
- An example of such group is but is not limited to the following group:
- pharmaceutically acceptable acid addition salts embraces salts with inorganic and organic acids, which include but are not limited to hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, citric acid, formic acid, fumaric acid, maleic acid, acetic acid, succinic acid, tartaric acid, methane-sulfonic acid, p-toluenesulfonic acid.
- Preferred groups for R 1 may be selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl.
- Preferred groups for R 2 maybe selected from the group consisting of methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cydohexyl, phenyl, CHF 2 and CF 3 .
- Preferred groups for R 3 may be selected from the group consisting of hydrogen, Cl and F.
- Preferred groups for R 4 maybe selected from the group consisting of hydrogen, methoxy, methylsulfonyl, Cl and F.
- R 5 may be selected from the group consisting of Br, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl, CF 3 O, PhO, methoxy, methylsulfonyl, Cl, F or I, and when R 5 is -NR 7 R 8 , R 7 and R 8 together with the nitrogen atom to which they are attached may form a group selected from the group consisting of piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl, pyrrolidin-1-yl, azetidine-1-yl, and azepan-1-yl, which maybe substituted by one or more F, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, t-butyl, hydroxy, methoxy, phenyl, dimethylarnino and 1,
- R 5 may be selected from the group consisting of Br, I, methyl, ethyl, propyl, i-propyl, butyl, i-butyl, and t-butyl, CF 3 O, PhO, methoxy, methylsulfonyl, Cl or F, and when R 5 is -NR 7 R 8 , R 7 and R 8 together with the nitrogen atom to which they are attached may form a group selected from the group consisting of piperidin-1-yl, 3,3-difiuoro-piperidin-l-yl, 4-hydroxy-4-methyl-piperidin-l-yl, 4- methoxy-piperidine-1-yl, morpholin-4-yl, pyrrolidin-1-yl, 2-methyl-pyrrolidin-l-yl, 4- methyl-piperazin-1-yl, 3-hydroxy-pyrrolidin-l-yl, 3-hydroxy-azetidine-l-yl, 4-hydroxy- 4phenyl
- Preferred compounds of the invention are those compounds of formula I, wherein
- R 1 is C 1 -C 7 alkyl
- R 2 is C r C 7 alkyl, phenyl, C r C 7 haloalkyl or C 3 -C 8 cycloalkyl;
- R 3 , R 4 are each independently hydrogen, halo, C 1 -C 7 alkoxy, CrC 7 alkylsulfonyl;
- R 5 is halo, Q-C 7 haloalkoxy, aryloxy, or is -NR 7 R 8 wherein R 7 and R 8 are Ci-C 7 alkyl, or R 7 and R 8 may, together with the nitrogen atom to which they are attached, form or a 4 to 8 membered heterocycloalkyl group which may be substituted by one or more subsituent(s) selected from the group consisting of halo, Ci-C 7 alkyl, hydroxy, Ci-C 7 alkoxy, phenyl and di(Ci-C 7 )alkylamino;
- R 6 is hydrogen or together with R 5 may form a 5 or 6 membered heterocycloalkyl group which may be substituted by one or more halogen.
- Also preferred compounds of the invention are those compounds of formula I wherein R 2 is CpC 7 alkyl, for example the following compounds: l-(6-Bromo-2-ethyl-4-phenyl-quinolin-3-yl)-propan-l-one; l-(6-Bromo-2-isobutyl-4-phenyl-quinolin-3-yl)-ethan.one; l-(6-Bromo-2-methyl-4-phenyl-quinolin-3-yl)-3-methyl-butan-l-one; l-[4-(4-Chloro-phenyl)-2-methyl-6-trifluoromethoxy-quinolin-3-yl]-ethanone; l-(6-Bromo-2-isopropyl-4-phenyl-quinolin-3-yl)-2-rriethyl-propan-l-one; l-[4-(3,4-Dichloro-phenyl)-2-methyl-6-triflu
- R 2 is Q-C 7 haloalkyl
- R 2 is Q-C 7 haloalkyl
- 2,2,2-trifluoro-ethanone 2,2,2-Trifluoro-l-[6-iodo-4-(4-methanesulfonyl-phenyl)-2-methyl-quinolin-3-yl]- ethanone; 2,2,2-Trifluoro- 1- [6-(4-hydroxy-4-methyl-piperidin-l-yl)-4-(4-methanesulfonyl- phenyl)-2-rnethyl-quinolin-3-yl] -ethanone; 2,2,2-Trifluoro-l-[4-(4-methanesulfonyl-phenyl)-6-(4-methox7-piperidin-l-yl)-2- methyl-quinolin-3-yl] -ethanone; l-[6-(3,3-Difluoro-piperidin-l-yl)-4-(4-methanesulfonyl-phenyl)-2-methyl-quino
- Still other preferred compounds of the invention are those compounds of formula I, wherein R 2 is C 3 -Cs cycloalkyl, for example the following compounds: [6-Bromo-4-(4-methanesulfonyl-phenyl)-2-methyl-quinolin-3-yl]-q ⁇ clopropyl- methanone;
- Still other preferred compounds of the invention are those compounds of formula I, wherein R" is phenyl, for example the following compounds:
- R 1 to R 6 are as defined in formula I. to give the compound of formula I; and if desired, converting the compound of formula I obtained into a pharmaceutically acceptable acid addition salt.
- the afore-mentioned compounds of formula I can also be manufactured in accordance with the invention by the following variant process comprising the step of reacting a compound of formula IV with a compound of formula V
- R 1 to R 8 are as defined in formula I; and if desired, converting the compound of formula Ia obtained into a pharmaceutically acceptable acid addition salt. It is understood that the compounds of formula Ia correspond to the compounds of formula I wherein R 5 is -NR 7 R 8 and R 7 and R 8 are as defined for formula I.
- the invention also encompasses a compound of formula I or Ia, whenever it is prepared according to the above-mentioned processes.
- the compounds of formula I and their pharmaceutically acceptable addition salts possess valuable pharmacological properties. It has been found that the compounds of the present invention have an affinity to the GABA B receptor.
- the Chinese Hamster Ovary (CHO) cells stably expressing human GABA B RI aR2a and G ⁇ l6 were seeded at 5xlO 4 cells/well in the poly-D-lysine treated, 96-well, black/ clear-bottomed plates (BD Biosciences, Palo Alto, CA). 24 h later, the cells were loaded for 90 min at 37°C with 4 ⁇ M Flou-4 acetoxymethyl ester (Catalog No. F- 14202, Molecular Probes, Eugene, OR) in loading buffer (IxHBSS, 20 roM HEPES, 2.5 mM Probenecid). Hanks' Balanced Salt Solution (HBSS) (10X) (catalog No.
- HBSS Hanks' Balanced Salt Solution
- the enhancers were applied 15 min before the application of the GABA.
- concentration-response curves of GABA (0.0003-30 ⁇ M) were determined in the absence and presence of 10 ⁇ M enhancer.
- the GABA-shift is defined as Log [EC 50 (GABA + 10 ⁇ M enhancer) / EC 50 (GABA alone)].
- the % maximum enhancing effect (% E max ) and potency (EC 50 value) of each enhancer was determined from concentration-response curve of the enhancer (0.001-30 ⁇ M) in the presence of 10 nM GABA (EQo).
- the compounds of formula I as well as their pharmaceutically usable acid addition salts can be used as medicaments, e.g. in the form of pharmaceutical preparations.
- the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coatec ⁇ tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
- the administration can, however, also be effected rectally, e.g. in the form of suppositories, or- parenterally, e.g. in the form of injection solutions.
- the compounds of formula I and their pharmaceutically usable acid addition salts can be processed with pharmaceutically inert, inorganic or organic excipients for the production of tablets, coated tablets, dragees and hard gelatine capsules. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc can be used as such excipients e.g. for tablets, dragees and hard gelatine capsules.
- Suitable excipients for soft gelatine capsules are e.g. vegetable oils, waxes, fats, semi ⁇ solid and liquid polyols.
- Suitable excipients for the manufacture of solutions and syrups include but are not limited to water, polyols, saccharose, invert sugar, glucose.
- Suitable excipients for injection solutions include but are not limited to water, alcohols, polyols, glycerol, vegetable oils.
- Suitable excipients for suppositories include but are not limited to natural or hardened oils, waxes, fats, semi-liquid or liquid polyols.
- the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 10 to 1000 mg per person of a compound of general formula I should be appropriate, although the above upper limit can also be exceeded when necessary.
- Tablet Formulation (Wet Granulation)
- Example Al (2-Amino-5-tert-butyl-phenyl)-phenyl-methanone
- the title compound was prepared following the general procedure of method C.
- a glass flask fitted with magnetic stir bar, rubber septum, thermometer, Hiclkmann- condenser, nitrogen-purged bubbler connected to a washing bottle containing 30 % NaOH the content of a fresh ampoule of gallium (III) chloride (5 g, 29 miriol) was added at once and then dissolved by the addition of 1,2-dichloroethane (80 mL).
- Xhis solution was cooled in ice, then 4-tert-butylaniline (36 mmol) was added slowly while keeping the temperature below 5 0 C.
- Example A3 (2-Amino-5-trifluoromethoxy-phenyl)-(4-chloro-phenyl)-metlianone
- Example 6 l-(6-Bromo-2-methyl-4-phenyl-quinolin-3-yl)-2,2-difluoro-ethanone
- the title compound was prepared from (2-Amino-5-bromo-phenyl)-phenyl- methanone [example A16] and 1,1-difluoroacetylacetone according to the procedure of example 1, except that the residue was purified by chromatography on amirxated silica gel with heptane/ethyl acetate (5:1). Yield: 36 %.
- MS: m/z 377 (M).
- Example 15 [4-(3-Chloro-phenyl)-2-methyl-6-trifluoromethoxy-quinolin-3-yl] -ethanone
- the glass vial was covered with a pressure-resistant seal, firmly locked by a screw-cap and heated with stirring in an oil bath at 120 0 C during 2h.
- the glass vial was cooled in ice before opening, the reaction mixture was diluted with heptane (5 mL) and filtered through a plug of Dicalite filter-aid and rinsed with heptane.
- Example 27 2-Trifluoro-l-(2-methyl-4-phenyl-6-pyrrolidin-l-yl-quinolin-3-yl)-ethanone
- Example 36 2,2,2-Trifluoro- l-[4-(4-fluoro-phenyl)-2-methyl-6-pyrroHdin-l-yl-quinolin-3-"yl]- ethanone
- Example 46 1- [6- (3-Dimethylamino-pyrrolidin- 1 -yl)-4- (4-fluoro-phenyl)- 2-methyl-quinolin-3-yl] -
- Example 52 1 - [6- (3 ,3-Difluoro-piperidin- 1 -yl)-4- (4-methanesulfo nyl-phenyl) -2-methyl- quinoKn-3-yl]-2,2,2-trifluoro-ethanorLe
- the title compound was prepared from (2-amino-5-trifiuoromethoxy-phenyl)- (4-fhiorophenyl) -methanone [example A9] and l-cydopropyl-l,3-butanedione according to the procedure of example 1, except that the solvent was isopropanol, the reaction time was of 16 h and heptane/ ethyl acetate (1:2) was used. Yield: 76 %; MS: m/z - 384 (M).
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020077012336A KR100876470B1 (en) | 2004-11-01 | 2005-10-25 | Quinoline as an Allosteric Enhancer of the BA-A Receptor |
EP05800636A EP1809605B1 (en) | 2004-11-01 | 2005-10-25 | Quinolines as allosteric enhancers of the gaba-b receptors |
CA002586066A CA2586066A1 (en) | 2004-11-01 | 2005-10-25 | Quinoline as allosteric enhancers of the gaba-b receptors |
MX2007005112A MX2007005112A (en) | 2004-11-01 | 2005-10-25 | Quinoline as allosteric enhancers of the gaba-b receptors. |
BRPI0517929-7A BRPI0517929A (en) | 2004-11-01 | 2005-10-25 | quinoline as allosteric enhancers of gaba-b receptors |
AT05800636T ATE477242T1 (en) | 2004-11-01 | 2005-10-25 | QUINOLINES AS ALLOSTERIC ENHANCERS OF GABA-B RECEPTORS |
DE602005022908T DE602005022908D1 (en) | 2004-11-01 | 2005-10-25 | CHINOLINES AS ALLOSTERIC ENHANCERS OF GABA B RECEPTORS |
JP2007538321A JP2008517963A (en) | 2004-11-01 | 2005-10-25 | Quinoline as an allosteric enhancer of GABA-B receptor |
AU2005300822A AU2005300822B2 (en) | 2004-11-01 | 2005-10-25 | Quinoline as allosteric enhancers of the GABA-B receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04105429 | 2004-11-01 | ||
EP04105429.7 | 2004-11-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006048146A1 true WO2006048146A1 (en) | 2006-05-11 |
Family
ID=35735244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/011403 WO2006048146A1 (en) | 2004-11-01 | 2005-10-25 | Quinoline as allosteric enhancers of the gaba-b receptors |
Country Status (16)
Country | Link |
---|---|
US (1) | US7576217B2 (en) |
EP (1) | EP1809605B1 (en) |
JP (1) | JP2008517963A (en) |
KR (1) | KR100876470B1 (en) |
CN (1) | CN101068788A (en) |
AR (1) | AR051612A1 (en) |
AT (1) | ATE477242T1 (en) |
AU (1) | AU2005300822B2 (en) |
BR (1) | BRPI0517929A (en) |
CA (1) | CA2586066A1 (en) |
DE (1) | DE602005022908D1 (en) |
ES (1) | ES2348246T3 (en) |
MX (1) | MX2007005112A (en) |
RU (1) | RU2378256C2 (en) |
TW (1) | TW200630341A (en) |
WO (1) | WO2006048146A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012116415A1 (en) * | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
US8551990B2 (en) | 2006-10-16 | 2013-10-08 | Bionomics Limited | Anxiolytic compounds |
US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
WO2015169999A1 (en) | 2014-05-09 | 2015-11-12 | Orion Corporation | Pharmacologically active quinazolinedione derivatives |
US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009041904A1 (en) * | 2007-09-27 | 2009-04-02 | Astrazeneca Ab | Quinoline compounds having an activity against the gabab receptor |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002371078A (en) * | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | Quinoline derivative and quinolone derivative |
WO2004043930A1 (en) * | 2002-11-13 | 2004-05-27 | Merck Sharp & Dohme Limited | Quinoline derivatives which enhance cognition via the gaba-a receptor |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
JPH0853419A (en) * | 1994-06-07 | 1996-02-27 | Takeda Chem Ind Ltd | Quinoline derivative and medicine containing the same |
US5641788A (en) * | 1994-06-07 | 1997-06-24 | Takeda Chemical Industries, Ltd. | Quinoline derivatives and pharmaceutical composition containing them |
ATE289593T1 (en) * | 1999-05-06 | 2005-03-15 | Neurogen Corp | SUBSTITUTED 4-OXO-QUINOLINE-3-CARBOXAMIDE AS GABA BRAIN RECEPTOR LIGANDS |
GB0209481D0 (en) | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
-
2005
- 2005-10-25 BR BRPI0517929-7A patent/BRPI0517929A/en not_active IP Right Cessation
- 2005-10-25 CA CA002586066A patent/CA2586066A1/en not_active Abandoned
- 2005-10-25 MX MX2007005112A patent/MX2007005112A/en active IP Right Grant
- 2005-10-25 JP JP2007538321A patent/JP2008517963A/en active Pending
- 2005-10-25 EP EP05800636A patent/EP1809605B1/en not_active Not-in-force
- 2005-10-25 CN CNA200580041562XA patent/CN101068788A/en active Pending
- 2005-10-25 WO PCT/EP2005/011403 patent/WO2006048146A1/en active Application Filing
- 2005-10-25 AU AU2005300822A patent/AU2005300822B2/en not_active Ceased
- 2005-10-25 RU RU2007115639/04A patent/RU2378256C2/en not_active IP Right Cessation
- 2005-10-25 AT AT05800636T patent/ATE477242T1/en active
- 2005-10-25 DE DE602005022908T patent/DE602005022908D1/en active Active
- 2005-10-25 KR KR1020077012336A patent/KR100876470B1/en not_active IP Right Cessation
- 2005-10-25 ES ES05800636T patent/ES2348246T3/en active Active
- 2005-10-27 US US11/259,860 patent/US7576217B2/en not_active Expired - Fee Related
- 2005-10-28 TW TW094138002A patent/TW200630341A/en unknown
- 2005-10-31 AR ARP050104541A patent/AR051612A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002371078A (en) * | 2001-06-12 | 2002-12-26 | Sankyo Co Ltd | Quinoline derivative and quinolone derivative |
WO2004043930A1 (en) * | 2002-11-13 | 2004-05-27 | Merck Sharp & Dohme Limited | Quinoline derivatives which enhance cognition via the gaba-a receptor |
Non-Patent Citations (11)
Title |
---|
ARCADI, A. ET AL.: "A Green Approach to the Friedländer Synthesis of Quinolines", SYNLETT., 2003, pages 203 - 206, XP002367353 * |
ChemDiv, Inc.; San Diego, CA, USA; Catalog Name: ChemDiv, Inc. Product Library; Publication Date 25 April 2003. * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SATO, SUSUMU ET AL: "Preparation of quinolines and quinolones and their use as cell adhesion inhibitors and cytokine formation inhibitors", XP002367441, retrieved from STN Database accession no. 2002:977034 * |
DATABASE CHEMCATS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002367442, retrieved from STN * |
DATABASE CHEMCATS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; XP002367443, retrieved from STN * |
FUSON, R. C.; MILLER, J. J.: "The Condensation of Grignard Reagents with 3-Pyridyl and 3-Quinolyl Ketones", J. AM. CHEM. SOC., vol. 79, 1957, pages 3477 - 3480, XP002367350 * |
Rare-Chemicals GmbH, Gettorf, Germany; Catalog Name: Rare Chemicals Catalogue; Publication Date: 27 September 2004. * |
SINSKY, M. S.; BASS, R. G.: "The Reaction of Some ortho-Substituted Anilines With Various alpha,beta-Acetylenic Ketones. A Route to Substituted Quinolines.", J. HETEROCYCL. CHEM., vol. 21, 1984, pages 759 - 768, XP002367352 * |
URWYLER S ET AL: "POSITIVE ALLOSTERIC MODULATION OF NATIVE AND RECOMBINANT GABAB RECEPTORS", AMERICAN CHEMICAL SOCIETY. ABSTRACTS OF PAPER. AT THE NATIONAL MEETING, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, US, vol. 225, no. 1/2, 23 March 2003 (2003-03-23), pages MEDI317, XP009029992, ISSN: 0065-7727 * |
URWYLER S ET AL: "POSITIVE ALLOSTERIC MODULATION OF NATIVE AND RECOMBINANT GAMMA-AMINOBUTYRIC ACIDB RECEPTORS BY 2,6-DI-TERT-BUTYL-4-(3-HYDROXY- 2,2-DIMETHYL-PROPYL)-PHENOL (CGP7930) AND ITS ALDEHYDE ANALOG CGP13501", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 60, no. 5, November 2001 (2001-11-01), pages 963 - 971, XP001153169, ISSN: 0026-895X * |
WALSER, A. ET AL.: "1,2,3,4-Tetrahydroquinolines and 1,2-Dihydroquinolines from 2-Aminobenzophenes", J. HETEROCYCL. CHEM., vol. 13, 1976, pages 131 - 133, XP002367351 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9975892B2 (en) | 2006-10-16 | 2018-05-22 | Bionomics Limited | Anxiolytic compounds |
US8551990B2 (en) | 2006-10-16 | 2013-10-08 | Bionomics Limited | Anxiolytic compounds |
US8614212B2 (en) | 2006-10-16 | 2013-12-24 | Bionomics Limited | Anxiolytic compounds |
US8906912B2 (en) | 2006-10-16 | 2014-12-09 | Bionomics Limited | Anxiolytic compounds |
US9573945B2 (en) | 2006-10-16 | 2017-02-21 | Bionomics Limited | Anxiolytic compounds |
US10233181B2 (en) | 2006-10-16 | 2019-03-19 | Bionomics Limited | Anxiolytic compounds |
US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
AU2012222874B2 (en) * | 2011-03-02 | 2015-04-16 | Bionomics Limited | Novel small-molecules as therapeutics |
US9023848B2 (en) | 2011-03-02 | 2015-05-05 | Bionomics Limited | Small-molecules as therapeutics |
WO2012116415A1 (en) * | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
US9133188B2 (en) | 2011-05-12 | 2015-09-15 | Bionomics Limited | Methods for preparing naphthyridines |
WO2015169999A1 (en) | 2014-05-09 | 2015-11-12 | Orion Corporation | Pharmacologically active quinazolinedione derivatives |
US11957673B2 (en) | 2017-09-07 | 2024-04-16 | Augusta University Research Institute, Inc. | Specific AKT3 activator and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20070085594A (en) | 2007-08-27 |
US20060094754A1 (en) | 2006-05-04 |
ATE477242T1 (en) | 2010-08-15 |
CN101068788A (en) | 2007-11-07 |
EP1809605B1 (en) | 2010-08-11 |
RU2378256C2 (en) | 2010-01-10 |
AU2005300822B2 (en) | 2010-12-02 |
KR100876470B1 (en) | 2008-12-31 |
CA2586066A1 (en) | 2006-05-11 |
AU2005300822A1 (en) | 2006-05-11 |
BRPI0517929A (en) | 2008-10-21 |
ES2348246T3 (en) | 2010-12-01 |
US7576217B2 (en) | 2009-08-18 |
DE602005022908D1 (en) | 2010-09-23 |
EP1809605A1 (en) | 2007-07-25 |
JP2008517963A (en) | 2008-05-29 |
TW200630341A (en) | 2006-09-01 |
RU2007115639A (en) | 2008-12-10 |
AR051612A1 (en) | 2007-01-24 |
MX2007005112A (en) | 2007-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1828199B1 (en) | Thieno-pyridine derivatives as gaba-b allosteric enhancers | |
US7576217B2 (en) | Quinolines as allosteric enhancers of the GABAB receptors | |
US7728142B2 (en) | 3-methanesulfonylquinolines as GABAB enhancers | |
BR112015001028B1 (en) | 5-HT3 RECEPTOR ANTAGONISTS, THEIR USE AND THE PHARMACEUTICAL COMPOSITION INCLUDING THEM | |
EP1725239B1 (en) | 4-(sulfanyl-pyrimidin-4-ylmethyl)-morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy | |
JP2009520014A (en) | Quinoline derivatives useful for the treatment of mGluR5 receptor-mediated disorders | |
KR101532101B1 (en) | Sulfonyl-Quinoline derivatives | |
Malherbe et al. | Quinolines as allosteric enhancers of the GABA-B receptors | |
Malherbe et al. | 3-Methanesulfonylquinolines as GABA-B enhancers | |
EP1915357A1 (en) | 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the gaba-b-receptor | |
Malherbe et al. | Thieno-pyridine derivatives as allosteric enhancers of the GABA-B receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005800636 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/005112 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2586066 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007538321 Country of ref document: JP Ref document number: 1857/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005300822 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005300822 Country of ref document: AU Date of ref document: 20051025 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077012336 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007115639 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580041562.X Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005800636 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0517929 Country of ref document: BR |